Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in thrombosis and coagulation therapy.

G Escolar1

  • 1Servicio de Hemoterapia y Hemostasia, Hospital Clínic, Barcelona, Spain.

Drug News & Perspectives
|December 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A freeze-dried platelet-derived hemostatic agent improves hemostasis in patients with severe thrombocytopenia before and after standard platelet transfusion: Studies ex vivo in the total thrombus-formation analysis system 01.

Transfusion·2026
Same author

Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis.

Platelets·2020
Same author

Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2019
Same author

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.

Drugs of today (Barcelona, Spain : 1998)·2018
Same author

Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: comment.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.

Drugs of today (Barcelona, Spain : 1998)·2017
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

This congress highlighted advancements in thrombosis and hematology, focusing on novel antithrombotic and antiplatelet agents. Key discussions included heparin safety, oral anticoagulation, and emerging therapeutic targets for platelet modulation.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • The 15th International Congress on Thrombosis convened to discuss critical updates in thrombosis, hemostasis, coagulation, and hematology.
  • The meeting addressed epidemiology, traditional anticoagulants, heparin-associated thrombocytopenia, and novel antithrombotic and antiplatelet agents.

Purpose of the Study:

  • To review the pharmacology and clinical applications of various heparins and new low molecular weight heparins (LMWHs).
  • To examine the efficacy and safety of oral anticoagulation therapies.
  • To explore emerging therapeutic targets and strategies for modulating platelet function and interactions.

Main Methods:

  • Presentations and lectures covered pharmacological, experimental, and clinical studies.

Related Experiment Videos

  • Extensive reviews of existing and novel antithrombotic and antiplatelet agents were conducted.
  • Discussions included the potential of targeting specific molecular pathways like collagen motifs, platelet receptors, macrophage proliferation, protein kinases, and PMN integrins.

    • Main Results:

    • New low molecular weight heparins (LMWHs) were presented.
    • Efficacy and safety data for oral anticoagulation were reviewed.
    • Novel antithrombotic drug development, including platelet function modulation and PMN integrin targeting, was a significant focus.

    Conclusions:

    • The congress provided a comprehensive update on thrombosis and hematology, emphasizing novel therapeutic strategies.
    • Emerging antithrombotic agents and targets, such as specific platelet inhibitors and PMN integrin modulation, show promise.
    • Further research into manipulating macrophage proliferation and protein kinase/phosphatase pathways may offer new therapeutic avenues.